Radiation optic neuropathy (RON) generally follows radiation therapy that exceed 50 Gy to the visual axis and occurs within three years of therapy. Currently, there are no universally accepted treatments or prophylaxis for RON. The review aimed to examine the efficacy of all treatments and prophylaxis for RON.
Methods
MEDLINE, Embase, the Cochrane Library, and gray literature were searched to December 2020. Studies on treatment(s) and/or prophylaxis of RON were included. Results were meta-analyzed using a random-effects model. Primary outcomes included the proportions of patients who experienced improvement, no change, or worsening of visual acuity (VA) for each treatment. Secondary outcome was the incidence of RON for studies on prophylaxis.
Results
Overall, 50 studies (n = 5397) were included. Meta-analysis (n = 1752) showed significantly lower incidence of RON in patients who underwent intravitreal anti-VEGF prophylaxis compared to control (RR 0.64, 95%CI [0.48, 0.86]) for uveal melanoma. Intravitreal anti-VEGF injections (n = 68), hyperbaric oxygen therapy alone (n = 14), and pentoxifylline (n = 5) resulted in improved or stable vision ≤1 logMAR in 54.5%, 42.9%, and 40.0% of patients, respectively. Systemic corticosteroids (n = 82), anticoagulants (n = 12), and systemic bevacizumab (n = 7) showed improved or stable vision ≤1 logMAR in 17.1%, 33.3%, and 14.3% of patients, respectively. Overall risk of bias was low, but evidence was limited to retrospective studies.
Conclusion
Intravitreal anti-VEGF injections reduced incidence of RON in irradiated uveal melanoma patients. Systemic corticosteroids, systemic bevacizumab, and warfarin alone are likely ineffective treatments. Early hyperbaric oxygen therapy and intravitreal anti-VEGF injections were most effective among those investigated and require further investigation.
ArcherELLiaoEATrobeJD. Radiation-Induced optic neuropathy: clinical and imaging profile of twelve patients. J Neuroophthalmol2019; 39: 170–180.
2.
LessellS. Friendly fire: neurogenic visual loss from radiation therapy. In: journal of neuro-ophthalmology. J Neuroophthalmol2004; 24: 243–250.
3.
RodenDBosleyTMFowbleB, et al.Delayed radiation injury to the retrobulbar optic nerves and chiasm: clinical syndrome and treatment with hyperbaric oxygen and corticosteroids. Ophthalmology1990; 97: 346–351.
4.
Van Den BerghACMSchoorlMADullaartRPF, et al.Lack of radiation optic neuropathy in 72 patients treated for pituitary adenoma. J Neuroophthalmol2004; 24: 200–205.
5.
BhandareNMonroeATMorrisCG, et al.Does altered fractionation influence the risk of radiation-induced optic neuropathy?Int J Radiat Oncol Biol Phys2005; 62: 1070–1077.
6.
ParsonsJTBovaFJFitzgeraldCR, et al.Radiation optic neuropathy after megavoltage external-beam irradiation - analysis of time-dose factors. Int J Radiat Oncol Biol Phys1994; 30: 755–763.
7.
BoschettiMDe LucchiMGiustiM, et al.Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with cushing disease. Eur J Endocrinol2006; 154: 813–818.
8.
ShrieveDCHazardLBoucherK, et al.Dose fractionation in stereotactic radiotherapy for parasellar meningiomas: radiobiological considerations of efficacy and optic nerve tolerance. J Neurosurg2004; 101: 390–395.
LeeMSBorruatFX. Should patients with radiation-induced optic neuropathy receive any treatment?J Neuroophthalmol2011; 31:: 83–88.
11.
BeckerMMastersonKDelavelleJ, et al.Imaging of the optic nerve. Eur J Radiol2010; 74: 299–313.
12.
GuyJSchatzNJ. Hyperbaric oxygen in the treatment of radiation-induced optic neuropathy. Ophthalmology1986; 93: 1083–1088.
13.
BennettMHFeldmeierJHampsonNB, et al.Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database of Systematic Reviews. USA: John Wiley and Sons Ltd; 2016. Vol. 2016.
14.
ShieldsCLDalvinLAChangM, et al.Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma comparison with nonrandomized historical control individuals. JAMA Ophthalmol2020; 138: 136–146.
15.
LiCQGersonSSnyderB. Case report: hyperbaric oxygen and MRI findings in radiation-induced optic neuropathy. Undersea Hyperb Med2014; 41: 59–63.
16.
LevyRLMillerNR. Hyperbaric oxygen therapy for radiation-induced optic neuropathy. Ann Acad Med Singap2006; 35: 151–157.
17.
BorruatFXSchatzNJGlaserJS, et al.Radiation optic neuropathy: report of cases, role of hyperbaric oxygen therapy, and literature review. Neuro-Ophthalmology1996; 16: 255–266.
18.
HigginsJPTGS (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0. UK: The Cochrane Collaboration. 2011.
19.
LiberatiAAltmanDGTetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed)2009; 62(10): e1–e34.
20.
SlimKNiniEForestierD, et al.Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg2003; 73: 712–716.
21.
The Cochrane Collaboration. GRADEpro GDT. UK: Cochrane Community, 2017.
22.
GuyattGHOxmanADVistGE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J2008; 336: 924–926.
23.
Schulze-BonselKFeltgenNBurauH, et al.Visual acuities “hand motion” and “counting fingers” can be quantified with the freiburg visual acuity TestInvestigative Ophthalmology and Visual Science2006; 47: 1236–1240.
24.
Schulze-BonselKFeltgenNBurauH, et al.Author Response: Numerical Imputation for Low Vision States Numerical Imputation for Low Vision States. Vol. 47. 2007.
25.
PatelHCongdonNStraussG, et al.A need for standardization in visual acuity measurement. Vol. 80, arquivos brasileiros de oftalmologia. Conselho Brasileiro De Oftalmologia2017; 80: 332–337.
26.
The Cochrane Collaboration. Review manager (RevMan) [computer program]. version 5.3. Copenhagen: The Nordic Cochrane Centre, 2014.
27.
LauJIoannidisJPATerrinN, et al.The case of the misleading funnel plot. British Medical Journal. BMJ Publishing Group2006; 333: 597–600.
28.
DoroslovackiPTamhankarMALiuGT, et al.Factors associated with occurrence of radiation-induced optic neuropathy at ``safe{‘‘} radiation dosage. Semin Ophthalmol2018; 33: 581–588.
29.
ZimmermanCFSchatzNJGlaserJS. Magnetic resonance imaging of radiation optic neuropathy. Am J Ophthalmol1990; 110: 389–394.
30.
MalikAGolnikK. Hyperbaric oxygen therapy in the treatment of radiation optic neuropathy. J Neuroophthalmol2012; 32: 128–131.
31.
AldreesSMicieliJA. Catastrophic vision loss from radiation-induced optic neuropathy. BMJ Case Rep2020; 13: e233706.
32.
WhippleKMLeviLLeeMS. The delayed cost of treatment. Surv Ophthalmol2013; 58: 370–376.
33.
DurisetiS. Stereotactic radiosurgery Re-irradiation for recurrent glioblastoma: a single institution experience. International Journal of Radiation Oncology2019; 103: E8–E9.
34.
GirkinCAComeyCHLunsfordLD, et al.Radiation optic neuropathy after stereotactic radiosurgery. Ophthalmology1997; 104: 1634–1643.
35.
Sánchez-OrgazMGrabowskaARoyo-OrejaA, et al.Optic neuropathy following orbital irradiation for Graves’ ophthalmopathy: a case report and literature review. Orbit. Orbit2012; 31:: 30–33.
36.
SiddiquiJDLoefflerJSMurphyMA. Radiation optic neuropathy after proton beam therapy for optic nerve sheath meningioma. J Neuroophthalmol2013; 33: 165–168.
37.
KimIKLaneAMJainP, et al.Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma. Trans Am Ophthalmol Soc2016; 114: T2.
38.
ShahSUShieldsCLBianciottoCG, et al.Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology2014; 121: 269–275.
39.
ChangMDalvinLAMazloumiM, et al.Prophylactic intravitreal bevacizumab after plaque radiotherapy for uveal melanoma: analysis of visual acuity, tumor response, and radiation complications in 1131 eyes based on patient age. Asia-Pacific Journal of Ophthalmology2020; 9: 29–38.
40.
SeibelICordiniDHagerA, et al.Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma. Graefes Archive for Clinical and Experimental Ophthalmology2016; 254: 1787–1792.
41.
RoelofsKLarocqueMPMurthaA, et al.The Use of intravitreal anti-VEGF and triamcinolone in the treatment of radiation papillopathy. Ocul Oncol Pathol2018; 4: 395–400.
42.
FingerPTChinKJ. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy. Int J Radiat Oncol Biol Phys2012; 82: 789–798.
43.
EcksteinDRiechardtAIHeufelderJ, et al.Radiation-induced optic neuropathy: observation versus intravitreal treatment: can visual acuity be maintained by intravitreal treatment?Am J Ophthalmol2019; 208: 289–294.
44.
ShermanJHAregawiDGLaiA, et al.Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology2009; 73: 1924–1926.
45.
KellyPJDinkinMJDrappatzJ, et al.Unexpected late radiation neurotoxicity following bevacizumab use: a case series. J Neuro-Oncol2011; 102: 485–490.
46.
LaiAFilkaEMcGibbonB, et al.Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for Up-front treatment of patients With newly diagnosed glioblastoma Multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys2008; 71: 1372–1380.
47.
FuBDDan BotaD. Optic neuropathy in glioma patients after receiving radiotherapy and bevacizumab: risk factors and related quality of life issues. Neuro Oncol2011; 13: 50–50.
48.
FarooqOLincoffNSSaikaliN, et al.Novel treatment for radiation optic neuropathy with intravenous bevacizumab. J Neuroophthalmol2012; 32: 321–324.
49.
FergusonIHuangJLeviL, et al.Radiation optic neuropathy after whole-brain radiation therapy. J Neuroophthalmol2019; 39: 383–387.
50.
ThomasABirzuCFeuvretL, et al.Radiation-induced optic neuropathy. Neuro Oncol2019; 21: 98–99.
AyoubEGuyJBMoulinN, et al.Radiation optic neuropathy and stroke suspicion. JMV-Journal de Medecine Vasculaire. France: Elsevier Masson SAS; 2020. p. 232–233. Vol. 45.
53.
BarbosaAPCarvalhoDMarquesL, et al.Inefficiency of the anticoagulant therapy in the regression of the radiation-induced optic neuropathy in Cushing's Disease. J Endocrinol Investig1999; 22: 301–305.
54.
Danesh-Meyer HVSavinoPJSergottRC. Visual loss despite anticoagulation in radiation-induced optic neuropathy. Clinical and Experimental Ophthalmology2004; 32: 333–335.
55.
GarrottHO’DayJ. Optic neuropathy secondary to radiotheraphy for nasal melanoma. Clinical and Experimental Ophthalmology2004; 32: 330–333.
56.
VenketasubramanianNGohKYChewP, et al.Anticoagulation for radiation-induced optic neuropathy. NEUROLOGY2001; 56: A37.
57.
ChahalHSLamAKhaderiSK. Is pentoxifylline Plus vitamin E an effective treatment for radiation-induced optic neuropathy?J Neuroophthalmol2013; 33: 91–93.
58.
MissottenGSONottingICSchlingemannRO, et al.Vascular endothelial growth factor A in eyes with uveal melanoma. Arch Ophthalmol2006; 124: 1428–1434.
59.
MillerJWLe CouterJStraussEC, et al.Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology2013; 120: 106–114.
60.
FalavarjaniKGNguyenQD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Basingstoke). UK: Nature Publishing Group; 2013. p. 787–794. Vol. 27.
61.
KimKJLiBWinerJ, et al.Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature1993; 362: 841–844.
62.
TyeKEngelhardHHSlavin KV, et al.An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neuro-Oncol2014; 117: 321–327.
63.
GonzalezJKumarAJConradCA, et al.Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys2007; 67: 323–326.
64.
WardAClissoldSP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs1987; 34: 50–97.
65.
ChiaoTBLeeAJ. Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. Ann Pharmacother2005; 39: 516–522.
66.
RizzoliHVPagnanelli DM. Treatment of delayed radiation necrosis of the brain. A clinical observation. J Neurosurg1984; 60(3): 589–594.
67.
MillerNR. Radiation-induced optic neuropathy: still no treatment. Clinical and Experimental Ophthalmology2004; 32: 233–235.
68.
ZhengBLinJLiY, et al.Predictors of the therapeutic effect of corticosteroids on radiation-induced optic neuropathy following nasopharyngeal carcinoma. Support Care Cancer2019; 27: 4213–4219.
69.
RyuSKolozsvaryAJenrowKA, et al.Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time. J Neuro-Oncol2007; 82: 119–124.
70.
KimJHBrownSLKolozsvaryA, et al.Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the Rat. Radiat Res2004; 161: 137–142.
71.
ThomSR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg2011; 127: 131S.
72.
MarxREEhlerWJTayapongsakP, et al.Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg1990; 160: 519–524.
73.
HeyboerMSharmaDSantiagoW, et al.Hyperbaric oxygen therapy: side effects defined and quantified. Adv Wound Care2017; 6: 210–224.
74.
SaremiFHelmyMFarzinS, et al.MRI Of cranial nerve enhancement. Am J Roentgenol2005; 185: 1487–1497.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
